|  |



Most Patients With HIV Opted for Injectable ART, PrEP in Phase 3 Trial

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.


View article...


Top stories of the last 30 days